Epilepsy burden in Kenya rises amid new research insights

Kenya faces a silent public health challenge that remains largely invisible to mainstream development discourse: an estimated 1-2 million citizens living with epilepsy, a chronic neurological condition affecting nearly 5% of the country's population. This substantial patient population represents not merely a health crisis, but a market inefficiency with significant implications for European healthcare investors and entrepreneurs seeking entry points into East Africa's underserved medical sectors. The global context underscores the scale of opportunity. The World Health Organization estimates 50 million epilepsy patients worldwide, yet developing economies like Kenya struggle with diagnosis rates below 30% and treatment gaps exceeding 70%. This disparity reflects a fundamental market failure: inadequate pharmaceutical distribution networks, insufficient diagnostic infrastructure, and limited specialist capacity across the region. Kenya's epilepsy burden stems from multiple converging factors. The country's tropical disease profile creates higher incidence rates of parasitic infections—particularly neurocysticercosis—a leading preventable cause of acquired epilepsy in sub-Saharan Africa. Simultaneously, road traffic accidents, perinatal complications, and limited access to emergency neurological care during acute brain injuries drive epilepsy incidence significantly above developed-market baselines. For every diagnosed case, healthcare analysts estimate 2-3 additional undiagnosed patients navigating the Kenyan healthcare system without treatment. From an investor perspective, this represents a